Adicet Bio, Inc. (ACET)
| Market Cap | 257.14M |
| Revenue (ttm) | 3.03M |
| Net Income (ttm) | -56.31M |
| Shares Out | 5.21M |
| EPS (ttm) | -1.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $13.10 |
| Previous Close | $13.42 |
| Change ($) | -0.32 |
| Change (%) | -2.38% |
| Day's Open | 13.40 |
| Day's Range | 2.28 - 13.44 |
| Day's Volume | 25,695 |
| 52-Week Range | 0.87 - 21.40 |
MENLO PARK, Calif. and BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cel...
Adicet Bio is a biotechnology company concentrated on developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a pre-clinical pipeline of 4 therap...
Adicet Bio (ACET) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies...
MENLO PARK, Calif. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cel...
MENLO PARK, Calif. and BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cel...
MENLO PARK, Calif. and BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cel...
MENLO PARK, Calif. and BOSTON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cel...
Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin's lymphoma Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients wit...
MENLO PARK, Calif. and BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
MENLO PARK, Calif. and BOSTON, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies ...
MENLO PARK, Calif. and BOSTON, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell...
MENLO PARK, Calif. and BOSTON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell...
MENLO PARK, Calif. and BOSTON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies...
MENLO PARK, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer...
- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology -
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to preve...
NEW YORK, July 28, 2020 /PRNewswire/ -- TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announced a coll...
BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind, placebo-...
NEW YORK, June 29, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of resTORbio, Inc. ("TORC" or th...
ResTORbio's Reverse Merger With Adicet Should Unlock Substantial Value For Shareholders
BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that due to the public health impact of the coronavirus pandemic and to prioritize the health and we...
BOSTON, April 03, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally...
ResTORbio Is Trading At Less Than Half Of Its Net Cash After Crash
The company's lead drug candidate flopped an important clinical trial, which has investors questioning the validity of the pipeline's approach.
There is a huge risk-reward factor in emerging pharmaceutical and biotech companies that happen to have all their eggs in just one basket.
Analysis indicates RTB101 upregulates innate antiviral immunity to prevent clinically symptomatic respiratory illnesses caused by multiple viruses in older adults Analysis indicates RTB101 upr...
BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to pre...
TORC has done tolerably well since IPO-ing last year, producing solid phase 2 results from lead drug candidate RTB101.
As of late, it has definitely been a great time to be an investor in resTORbio.
About ACET
Adicet Bio, a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors or T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Its products pipeline includes ADI-001, which is in Phase 1 clinical study to treat non-Hodgkin's lymphoma; and ADI-002 that is in Phase 1 clinical... [Read more...]
| Industry Medicinal and Botanical Manufacturing | Founded 1947 |
| CEO Chen Schor | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol ACET |
Analyst Forecasts
According to 3 analysts, the average rating for Adicet Bio stock is "Strong Buy." The 12-month stock price forecast is 28.25, which is an increase of 115.65% from the latest price.